: Most-Cited Full-Text Articles http://ard.bmj.com Most-cited rankings are recalculated at the beginning of the month based on citations to articles on this journal site from articles in other HighWire-hosted journals. 2026-06-08 <![CDATA[2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative]]> http://ard.bmj.com/cgi/content/short/annrheumdis;69/9/1580?rss=1&ssource=mfc Sep 1, 2010; 69:1580-1588
Criteria]]> Daniel Aletaha 2010-09-01 10.1136/ard.2010.138461 BMJ Publishing Group Ltd 9 69 1588 2010-09-01 Criteria 1580 <![CDATA[The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection]]> http://ard.bmj.com/cgi/content/short/annrheumdis;68/6/777?rss=1&ssource=mfc Jun 1, 2009; 68:777-783
Clinical and epidemiological research]]> M Rudwaleit 2009-06-01 10.1136/ard.2009.108233 BMJ Publishing Group Ltd 6 68 783 2009-06-01 Clinical and epidemiological research 777 <![CDATA[Treating rheumatoid arthritis to target: recommendations of an international task force]]> http://ard.bmj.com/cgi/content/short/annrheumdis;69/4/631?rss=1&ssource=mfc Apr 1, 2010; 69:631-637
Recommendations]]> Josef S Smolen 2010-04-01 10.1136/ard.2009.123919 BMJ Publishing Group Ltd 4 69 637 2010-04-01 Recommendations 631 <![CDATA[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update]]> http://ard.bmj.com/cgi/content/short/annrheumdis;76/6/960?rss=1&ssource=mfc Jun 1, 2017; 76:960-977
Recommendations]]> Josef S Smolen 2017-06-01 10.1136/annrheumdis-2016-210715 BMJ Publishing Group Ltd 6 76 977 2017-06-01 Recommendations 960 <![CDATA[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs]]> http://ard.bmj.com/cgi/content/short/annrheumdis;69/6/964?rss=1&ssource=mfc Jun 1, 2010; 69:964-975
Recommendations]]> Josef S Smolen 2010-06-01 10.1136/ard.2009.126532 BMJ Publishing Group Ltd 6 69 975 2010-06-01 Recommendations 964 <![CDATA[American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials]]> http://ard.bmj.com/cgi/content/short/annrheumdis;70/3/404?rss=1&ssource=mfc Mar 1, 2011; 70:404-413
Criteria]]> David T Felson 2011-03-01 10.1136/ard.2011.149765 BMJ Publishing Group Ltd 3 70 413 2011-03-01 Criteria 404 <![CDATA[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update]]> http://ard.bmj.com/cgi/content/short/annrheumdis;73/3/492?rss=1&ssource=mfc Mar 1, 2014; 73:492-509
Recommendations]]> Josef S Smolen 2014-03-01 10.1136/annrheumdis-2013-204573 BMJ Publishing Group Ltd 3 73 509 2014-03-01 Recommendations 492 <![CDATA[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update]]> http://ard.bmj.com/cgi/content/short/annrheumdis;79/6/685?rss=1&ssource=mfc Jun 1, 2020; 79:685-699
Recommendations]]> Josef S Smolen 2020-06-01 10.1136/annrheumdis-2019-216655 BMJ Publishing Group Ltd 6 79 699 2020-06-01 Recommendations 685 <![CDATA[2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative]]> http://ard.bmj.com/cgi/content/short/annrheumdis;72/11/1747?rss=1&ssource=mfc Nov 1, 2013; 72:1747-1755
Criteria]]> Frank van den Hoogen 2013-11-01 10.1136/annrheumdis-2013-204424 BMJ Publishing Group Ltd 11 72 1755 2013-11-01 Criteria 1747 <![CDATA[2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations]]> http://ard.bmj.com/cgi/content/short/annrheumdis;74/1/8?rss=1&ssource=mfc Jan 1, 2015; 74:8-13
Recommendations]]> D&eacute;sir&eacute;e van der Heijde 2015-01-01 10.1136/annrheumdis-2014-206350 BMJ Publishing Group Ltd 1 74 13 2015-01-01 Recommendations 8 <![CDATA[EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis]]> http://ard.bmj.com/cgi/content/short/annrheumdis;69/2/325?rss=1&ssource=mfc Feb 1, 2010; 69:325-331
Recommendations]]> M J L Peters 2010-02-01 10.1136/ard.2009.113696 BMJ Publishing Group Ltd 2 69 331 2010-02-01 Recommendations 325 <![CDATA[Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis]]> http://ard.bmj.com/cgi/content/short/annrheumdis;68/1/18?rss=1&ssource=mfc Jan 1, 2009; 68:18-24
Clinical and epidemiological research]]> C Lukas 2009-01-01 10.1136/ard.2008.094870 BMJ Publishing Group Ltd 1 68 24 2009-01-01 Clinical and epidemiological research 18 <![CDATA[Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force]]> http://ard.bmj.com/cgi/content/short/annrheumdis;75/1/3?rss=1&ssource=mfc Jan 1, 2016; 75:3-15
Recommendations]]> Josef S Smolen 2016-01-01 10.1136/annrheumdis-2015-207524 BMJ Publishing Group Ltd 1 75 15 2016-01-01 Recommendations 3 <![CDATA[Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry]]> http://ard.bmj.com/cgi/content/short/annrheumdis;79/7/859?rss=1&ssource=mfc Jul 1, 2020; 79:859-866
Epidemiology]]> Milena Gianfrancesco 2020-07-01 10.1136/annrheumdis-2020-217871 BMJ Publishing Group Ltd 7 79 866 2020-07-01 Epidemiology 859 <![CDATA[The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general]]> http://ard.bmj.com/cgi/content/short/annrheumdis;70/1/25?rss=1&ssource=mfc Jan 1, 2011; 70:25-31
Criteria]]> M Rudwaleit 2011-01-01 10.1136/ard.2010.133645 BMJ Publishing Group Ltd 1 70 31 2011-01-01 Criteria 25 <![CDATA[2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis]]> http://ard.bmj.com/cgi/content/short/annrheumdis;76/6/978?rss=1&ssource=mfc Jun 1, 2017; 76:978-991
Recommendations]]> D&eacute;sir&eacute;e van der Heijde 2017-06-01 10.1136/annrheumdis-2016-210770 BMJ Publishing Group Ltd 6 76 991 2017-06-01 Recommendations 978 <![CDATA[The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal]]> http://ard.bmj.com/cgi/content/short/annrheumdis;68/6/770?rss=1&ssource=mfc Jun 1, 2009; 68:770-776
Clinical and epidemiological research]]> M Rudwaleit 2009-06-01 10.1136/ard.2009.108217 BMJ Publishing Group Ltd 6 68 776 2009-06-01 Clinical and epidemiological research 770 <![CDATA[IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial]]> http://ard.bmj.com/cgi/content/short/annrheumdis;67/11/1516?rss=1&ssource=mfc Nov 1, 2008; 67:1516-1523
Clinical and epidemiological research]]> P Emery 2008-11-01 10.1136/ard.2008.092932 BMJ Publishing Group Ltd 11 67 1523 2008-11-01 Clinical and epidemiological research 1516 <![CDATA[Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores]]> http://ard.bmj.com/cgi/content/short/annrheumdis;70/1/47?rss=1&ssource=mfc Jan 1, 2011; 70:47-53
Clinical and epidemiological research]]> Pedro Machado 2011-01-01 10.1136/ard.2010.138594 BMJ Publishing Group Ltd 1 70 53 2011-01-01 Clinical and epidemiological research 47 <![CDATA[The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study]]> http://ard.bmj.com/cgi/content/short/annrheumdis;73/7/1323?rss=1&ssource=mfc Jul 1, 2014; 73:1323-1330
Clinical and epidemiological research]]> Marita Cross 2014-07-01 10.1136/annrheumdis-2013-204763 BMJ Publishing Group Ltd 7 73 1330 2014-07-01 Clinical and epidemiological research 1323 <![CDATA[Changes in causes of death in systemic sclerosis, 1972-2002]]> http://ard.bmj.com/cgi/content/short/annrheumdis;66/7/940?rss=1&ssource=mfc Jul 1, 2007; 66:940-944
Extended reports]]> Virginia D Steen 2007-07-01 10.1136/ard.2006.066068 BMJ Publishing Group Ltd 7 66 944 2007-07-01 Extended reports 940 <![CDATA[EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update]]> http://ard.bmj.com/cgi/content/short/annrheumdis;82/1/3?rss=1&ssource=mfc Jan 1, 2023; 82:3-18
Recommendations]]> Josef S Smolen 2023-01-01 10.1136/ard-2022-223356 BMJ Publishing Group Ltd 1 82 18 2023-01-01 Recommendations 3 <![CDATA[2019 update of the EULAR recommendations for the management of systemic lupus erythematosus]]> http://ard.bmj.com/cgi/content/short/annrheumdis;78/6/736?rss=1&ssource=mfc Jun 1, 2019; 78:736-745
Recommendations]]> Antonis Fanouriakis 2019-06-01 10.1136/annrheumdis-2019-215089 BMJ Publishing Group Ltd 6 78 745 2019-06-01 Recommendations 736 <![CDATA[The global burden of low back pain: estimates from the Global Burden of Disease 2010 study]]> http://ard.bmj.com/cgi/content/short/annrheumdis;73/6/968?rss=1&ssource=mfc Jun 1, 2014; 73:968-974
Clinical and epidemiological research]]> Damian Hoy 2014-06-01 10.1136/annrheumdis-2013-204428 BMJ Publishing Group Ltd 6 73 974 2014-06-01 Clinical and epidemiological research 968 <![CDATA[Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment]]> http://ard.bmj.com/cgi/content/short/annrheumdis;69/01/48?rss=1&ssource=mfc Jan 1, 2010; 69:48-53
Clinical and epidemiological research]]> L C Coates 2010-01-01 10.1136/ard.2008.102053 BMJ Publishing Group Ltd 01 69 53 2010-01-01 Clinical and epidemiological research 48 <![CDATA[Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)]]> http://ard.bmj.com/cgi/content/short/annrheumdis;75/9/1615?rss=1&ssource=mfc Sep 1, 2016; 75:1615-1621
Clinical and epidemiological research]]> Kate Franklyn 2016-09-01 10.1136/annrheumdis-2015-207726 BMJ Publishing Group Ltd 9 75 1621 2016-09-01 Clinical and epidemiological research 1615 <![CDATA[Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system]]> http://ard.bmj.com/cgi/content/short/annrheumdis;64/1/127?rss=1&ssource=mfc Jan 1, 2005; 64:127-129
Concise reports]]> M C W Creemers 2005-01-01 10.1136/ard.2004.020503 BMJ Publishing Group Ltd 1 64 129 2005-01-01 Concise reports 127 <![CDATA[Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.]]> http://ard.bmj.com/cgi/content/short/annrheumdis;49/11/916?rss=1&ssource=mfc Nov 1, 1990; 49:916-920
Research Article]]> D M van der Heijde 1990-11-01 10.1136/ard.49.11.916 BMJ Publishing Group Ltd 11 49 920 1990-11-01 Research Article 916 <![CDATA[Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database]]> http://ard.bmj.com/cgi/content/short/annrheumdis;69/10/1809?rss=1&ssource=mfc Oct 1, 2010; 69:1809-1815
Clinical and epidemiological research]]> Anthony J Tyndall 2010-10-01 10.1136/ard.2009.114264 BMJ Publishing Group Ltd 10 69 1815 2010-10-01 Clinical and epidemiological research 1809 <![CDATA[European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update]]> http://ard.bmj.com/cgi/content/short/annrheumdis;75/3/499?rss=1&ssource=mfc Mar 1, 2016; 75:499-510
Clinical and epidemiological research]]> L Gossec 2016-03-01 10.1136/annrheumdis-2015-208337 BMJ Publishing Group Ltd 3 75 510 2016-03-01 Clinical and epidemiological research 499 <![CDATA[ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis]]> http://ard.bmj.com/cgi/content/short/annrheumdis;68/12/1811?rss=1&ssource=mfc Dec 1, 2009; 68:1811-1818
Clinical and epidemiological research]]> D van der Heijde 2009-12-01 10.1136/ard.2008.100826 BMJ Publishing Group Ltd 12 68 1818 2009-12-01 Clinical and epidemiological research 1811 <![CDATA[EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)]]> http://ard.bmj.com/cgi/content/short/annrheumdis;65/10/1312?rss=1&ssource=mfc Oct 1, 2006; 65:1312-1324
Extended reports]]> W Zhang 2006-10-01 10.1136/ard.2006.055269 BMJ Publishing Group Ltd 10 65 1324 2006-10-01 Extended reports 1312 <![CDATA[The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis]]> http://ard.bmj.com/cgi/content/short/annrheumdis;68/Suppl_2/ii1?rss=1&ssource=mfc Jun 1, 2009; 68:ii1-ii44
Supplement]]> J Sieper 2009-06-01 10.1136/ard.2008.104018 BMJ Publishing Group Ltd Suppl_2 68 ii44 2009-06-01 Supplement ii1 <![CDATA[Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies]]> http://ard.bmj.com/cgi/content/short/annrheumdis;71/9/1524?rss=1&ssource=mfc Sep 1, 2012; 71:1524-1529
Clinical and epidemiological research]]> Juan Antonio Avina-Zubieta 2012-09-01 10.1136/annrheumdis-2011-200726 BMJ Publishing Group Ltd 9 71 1529 2012-09-01 Clinical and epidemiological research 1524 <![CDATA[Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group]]> http://ard.bmj.com/cgi/content/short/annrheumdis;68/10/1520?rss=1&ssource=mfc Oct 1, 2009; 68:1520-1527
Clinical and epidemiological research]]> M Rudwaleit 2009-10-01 10.1136/ard.2009.110767 BMJ Publishing Group Ltd 10 68 1527 2009-10-01 Clinical and epidemiological research 1520 <![CDATA[EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT)]]> http://ard.bmj.com/cgi/content/short/annrheumdis;62/12/1145?rss=1&ssource=mfc Dec 1, 2003; 62:1145-1155
Extended reports]]> K M Jordan 2003-12-01 10.1136/ard.2003.011742 BMJ Publishing Group Ltd 12 62 1155 2003-12-01 Extended reports 1145 <![CDATA[EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update]]> http://ard.bmj.com/cgi/content/short/annrheumdis;76/1/17?rss=1&ssource=mfc Jan 1, 2017; 76:17-28
Recommendations]]> R Agca 2017-01-01 10.1136/annrheumdis-2016-209775 BMJ Publishing Group Ltd 1 76 28 2017-01-01 Recommendations 17 <![CDATA[2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus]]> http://ard.bmj.com/cgi/content/short/annrheumdis;78/9/1151?rss=1&ssource=mfc Sep 1, 2019; 78:1151-1159
Criteria]]> Martin Aringer 2019-09-01 10.1136/annrheumdis-2018-214819 BMJ Publishing Group Ltd 9 78 1159 2019-09-01 Criteria 1151 <![CDATA[Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythroG]]> http://ard.bmj.com/cgi/content/short/annrheumdis;68/6/954?rss=1&ssource=mfc Jun 1, 2009; 68:954-960
Clinical and epidemiological research]]> G Wells 2009-06-01 10.1136/ard.2007.084459 BMJ Publishing Group Ltd 6 68 960 2009-06-01 Clinical and epidemiological research 954 <![CDATA[Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database]]> http://ard.bmj.com/cgi/content/short/annrheumdis;66/6/754?rss=1&ssource=mfc Jun 1, 2007; 66:754-763
Extended reports]]> U A Walker 2007-06-01 10.1136/ard.2006.062901 BMJ Publishing Group Ltd 6 66 763 2007-06-01 Extended reports 754 <![CDATA[2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis]]> http://ard.bmj.com/cgi/content/short/annrheumdis;70/6/896?rss=1&ssource=mfc Jun 1, 2011; 70:896-904
Recommendations]]> J Braun 2011-06-01 10.1136/ard.2011.151027 BMJ Publishing Group Ltd 6 70 904 2011-06-01 Recommendations 896 <![CDATA[Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)]]> http://ard.bmj.com/cgi/content/short/annrheumdis;66/11/1443?rss=1&ssource=mfc Nov 1, 2007; 66:1443-1449
Extended reports]]> S M M Verstappen 2007-11-01 10.1136/ard.2007.071092 BMJ Publishing Group Ltd 11 66 1449 2007-11-01 Extended reports 1443 <![CDATA[2016 updated EULAR evidence-based recommendations for the management of gout]]> http://ard.bmj.com/cgi/content/short/annrheumdis;76/1/29?rss=1&ssource=mfc Jan 1, 2017; 76:29-42
Recommendations]]> P Richette 2017-01-01 10.1136/annrheumdis-2016-209707 BMJ Publishing Group Ltd 1 76 42 2017-01-01 Recommendations 29 <![CDATA[EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees]]> http://ard.bmj.com/cgi/content/short/annrheumdis;63/9/1172?rss=1&ssource=mfc Sep 1, 2004; 63:1172-1176
EULAR reports]]> M Dougados 2004-09-01 10.1136/ard.2004.023697 BMJ Publishing Group Ltd 9 63 1176 2004-09-01 EULAR reports 1172 <![CDATA[EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)]]> http://ard.bmj.com/cgi/content/short/annrheumdis;66/1/34?rss=1&ssource=mfc Jan 1, 2007; 66:34-45
Extended reports]]> B Combe 2007-01-01 10.1136/ard.2005.044354 BMJ Publishing Group Ltd 1 66 45 2007-01-01 Extended reports 34 <![CDATA[Treat-to-target in systemic lupus erythematosus: recommendations from an international task force]]> http://ard.bmj.com/cgi/content/short/annrheumdis;73/6/958?rss=1&ssource=mfc Jun 1, 2014; 73:958-967
Recommendations]]> Ronald F van Vollenhoven 2014-06-01 10.1136/annrheumdis-2013-205139 BMJ Publishing Group Ltd 6 73 967 2014-06-01 Recommendations 958 <![CDATA[EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update]]> http://ard.bmj.com/cgi/content/short/annrheumdis;79/6/700?rss=1&ssource=mfc Jun 1, 2020; 79:700-712
Recommendations]]> Laure Gossec 2020-06-01 10.1136/annrheumdis-2020-217159 BMJ Publishing Group Ltd 6 79 712 2020-06-01 Recommendations 700 <![CDATA[Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies]]> http://ard.bmj.com/cgi/content/short/annrheumdis;79/5/667?rss=1&ssource=mfc May 1, 2020; 79:667-668
Letters]]> Sara Monti 2020-05-01 10.1136/annrheumdis-2020-217424 BMJ Publishing Group Ltd 5 79 668 2020-05-01 Letters 667 <![CDATA[Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort]]> http://ard.bmj.com/cgi/content/short/annrheumdis;74/9/1706?rss=1&ssource=mfc Sep 1, 2015; 74:1706-1713
Clinical and epidemiological research]]> Ian N Bruce 2015-09-01 10.1136/annrheumdis-2013-205171 BMJ Publishing Group Ltd 9 74 1713 2015-09-01 Clinical and epidemiological research 1706 <![CDATA[Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study]]> http://ard.bmj.com/cgi/content/short/annrheumdis;69/01/88?rss=1&ssource=mfc Jan 1, 2010; 69:88-96
Clinical and epidemiological research]]> G Jones 2010-01-01 10.1136/ard.2008.105197 BMJ Publishing Group Ltd 01 69 96 2010-01-01 Clinical and epidemiological research 88